Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats
Authors:
- Kenji UeharaKUKenji Uehara
- Toshiki SudoTSToshiki Sudo
- Keiko MarukawaKMKeiko Marukawa
- Yoshinobu YasudaYYYoshinobu Yasuda
- Yukio KimuraYKYukio Kimura
- 1 October 2000
- journal article
- Published by Elsevier in Atherosclerosis
- Vol. 152 (2) , 299-305
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Cholesteryl ester transfer activity in lipoprotein lipase deficiency and other primary hypertriglyceridemiasClinica Chimica Acta, 1993
- Plasma triglyceride and coronary heart disease.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991
- Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human plateletsBiochemical Pharmacology, 1988
- Effects of Cilostazol, a Selective cAMP Phosphodiesterase Inhibitor on the Contraction of Vascular Smooth MusclePharmacology, 1988
- Cyclic AMP and cyclic GMP phosphodiesterases: Target for drug developmentDrug Development Research, 1988
- Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility.Circulation Research, 1987
- A New Generation of Phosphodiesterase Inhibitors: Multiple Molecular Forms of Phosphodiesterase and the Potential for Drug SelectivityJournal of Medicinal Chemistry, 1985
- Positive Inotropic AgentsAnnual Review of Pharmacology and Toxicology, 1984
- High density lipoprotein subfractions in relation to lipoprotein lipase activity of tissues in man—evidence for reciprocal regulation of HDL2 and HDL3 levels by lipoprotein lipaseClinica Chimica Acta, 1981
- Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro.Proceedings of the National Academy of Sciences, 1978